Tag: common share

HF Foods Reports Second Quarter 2025 Financial Results

Reports Quarterly Record Net Revenue and Gross Profit

Reports Quarterly Record Net Revenue and Gross Profit

HighPeak Energy, Inc. Announces Second Quarter 2025 Financial and Operating Results

FORT WORTH, Texas, Aug. 11, 2025 (GLOBE NEWSWIRE) -- HighPeak Energy, Inc. (“HighPeak” or the “Company”) (NASDAQ: HPK) today announced financial and operating results for the quarter ended June 30, 2025.

Lincoln Educational Services Reports Second Quarter Results and Increases Outlook for Full Year 2025

Conference Call Today at 10:00 a.m. Eastern Daylight Time

Conference Call Today at 10:00 a.m. Eastern Daylight Time

Oxy Capital Announces Disposition of Montero Mining and Exploration Ltd. Common Shares

LISBON, Portugal, Aug. 11, 2025 /CNW/ - Oxy Capital SGOIC, S.A ("Oxy Capital") is pleased to announce that it has disposed of its holding of...

International Petroleum Corporation Announces Results of Normal Course Issuer Bid

TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- International Petroleum Corporation (IPC or the Corporation) (TSX, Nasdaq Stockholm: IPCO) is pleased to announce that IPC repurchased a total of 98,900 IPC common shares (ISIN: CA46016U1084) during the period of August 4 to 8, 2025 under IPC’s normal course issuer bid / share repurchase program (NCIB).

First National Bank Alaska announces unaudited results for second quarter 2025

ANCHORAGE, Alaska, Aug. 08, 2025 (GLOBE NEWSWIRE) -- First National Bank Alaska’s (OTCQX:FBAK) net income for the second quarter of 2025 was $18.4 million, or $5.80 per share. This compares to a net income of $15.6 million, or $4.94 per share, for the same period in 2024.

XORTX Completes USD $114,500 Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES
OR FOR DISSEMINATION IN THE UNITED STATES

Prospect Park Provides Corporate and Business Update

VANCOUVER, British Columbia, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Prospect Park Capital Corp. (the “Company”) is pleased to announce the following updates:

Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results

TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and nine months ended June 30, 2025 and provided an update on its business.

Clarke Inc. Reports Refinancing of Credit Facilities and 2025 Second Quarter Results

HALIFAX, NS, Aug. 8, 2025 /CNW/ - Clarke Inc. ("Clarke" or the "Company") (TSX: CKI) today announced its results for the three and six...

Stellus Private Credit BDC Reports Results for its Second Fiscal Quarter Ended June 30, 2025

HOUSTON, Aug. 8, 2025 /PRNewswire/ -- Stellus Private Credit BDC ("Stellus PBDC", "we", or the "Company") today announced financial results for its second fiscal...

KOPPERS REPORTS SECOND QUARTER 2025 RESULTS; REVISES 2025 OUTLOOK

Sales of $504.8 Million vs. $563.2 Million in Prior Year QuarterNet income attributable to Koppers of $16.4 Million vs. $26.8 Million in Prior Year...

Boralex reports second quarter operating income comparable to 2024 and actively pursue its development and construction activities

MONTREAL, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Boralex Inc. (“Boralex” or the “Corporation”) (TSX: BLX) is pleased to report its results for the second quarter of 2025.

Calumet Reports Second Quarter 2025 Results

Second quarter 2025 net loss of $147.9 million, or basic loss per common share of $1.70 per shareSecond quarter 2025 Adjusted EBITDA with Tax...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Company Name

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Phone

This field is for validation purposes and should be left unchanged.

HomeTagsCommon share

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress